Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy
With the rising prevalence of antimicrobial resistance, the eradication rates of Helicobacter pylori (H. pylori) with standard treatments are decreasing to unacceptable levels (i.e., ≤80%) in most countries. After these disappointing results, several authorities have proposed that infection with H....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/757926 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548669554950144 |
|---|---|
| author | Sotirios D. Georgopoulos Vasilios Papastergiou Stylianos Karatapanis |
| author_facet | Sotirios D. Georgopoulos Vasilios Papastergiou Stylianos Karatapanis |
| author_sort | Sotirios D. Georgopoulos |
| collection | DOAJ |
| description | With the rising prevalence of antimicrobial resistance, the eradication rates of Helicobacter pylori (H. pylori) with standard treatments are decreasing to unacceptable levels (i.e., ≤80%) in most countries. After these disappointing results, several authorities have proposed that infection with H. pylori should be approached and treated as any other bacterial infectious disease. This implicates that clinicians should prescribe empirical treatments yielding a per protocol eradication of at least 90%. In recent years several treatments producing ≥90% cure rates have been proposed including sequential therapy, concomitant quadruple therapy, hybrid (dual-concomitant) therapy, and bismuth-containing quadruple therapy. These treatments are likely to represent the recommended first-line treatments in the near future. In the present paper, we are considering a series of critical issues regarding currently available means and approaches for the management of H. pylori infection. Clinical needs and realistic endpoints are taken into account. Furthermore, emerging strategies for the eradication of H. pylori and the existing evidence of their clinical validation and widespread applicability are discussed. |
| format | Article |
| id | doaj-art-38eab1099bee40dfa1b10208b4fd0623 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-38eab1099bee40dfa1b10208b4fd06232025-02-03T06:13:18ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/757926757926Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved EfficacySotirios D. Georgopoulos0Vasilios Papastergiou1Stylianos Karatapanis2Department of Gastroenterology, Athens Medical Center of P. Phaliron, P. Phaliron, 17562 Athens, GreeceDepartment of Internal Medicine, General Hospital of Rhodes, 85100 Rhodes, GreeceDepartment of Internal Medicine, General Hospital of Rhodes, 85100 Rhodes, GreeceWith the rising prevalence of antimicrobial resistance, the eradication rates of Helicobacter pylori (H. pylori) with standard treatments are decreasing to unacceptable levels (i.e., ≤80%) in most countries. After these disappointing results, several authorities have proposed that infection with H. pylori should be approached and treated as any other bacterial infectious disease. This implicates that clinicians should prescribe empirical treatments yielding a per protocol eradication of at least 90%. In recent years several treatments producing ≥90% cure rates have been proposed including sequential therapy, concomitant quadruple therapy, hybrid (dual-concomitant) therapy, and bismuth-containing quadruple therapy. These treatments are likely to represent the recommended first-line treatments in the near future. In the present paper, we are considering a series of critical issues regarding currently available means and approaches for the management of H. pylori infection. Clinical needs and realistic endpoints are taken into account. Furthermore, emerging strategies for the eradication of H. pylori and the existing evidence of their clinical validation and widespread applicability are discussed.http://dx.doi.org/10.1155/2012/757926 |
| spellingShingle | Sotirios D. Georgopoulos Vasilios Papastergiou Stylianos Karatapanis Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy Gastroenterology Research and Practice |
| title | Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy |
| title_full | Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy |
| title_fullStr | Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy |
| title_full_unstemmed | Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy |
| title_short | Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy |
| title_sort | helicobacter pylori eradication therapies in the era of increasing antibiotic resistance a paradigm shift to improved efficacy |
| url | http://dx.doi.org/10.1155/2012/757926 |
| work_keys_str_mv | AT sotiriosdgeorgopoulos helicobacterpylorieradicationtherapiesintheeraofincreasingantibioticresistanceaparadigmshifttoimprovedefficacy AT vasiliospapastergiou helicobacterpylorieradicationtherapiesintheeraofincreasingantibioticresistanceaparadigmshifttoimprovedefficacy AT stylianoskaratapanis helicobacterpylorieradicationtherapiesintheeraofincreasingantibioticresistanceaparadigmshifttoimprovedefficacy |